Nivolumab efficacy in leptomeningeal metastasis of renal cell carcinoma: a case report
Autor: | Laura Ghilardi, Marco Roscigno, Lucia Bonomi, Carlo Tondini, Ornella Manara, Alessandra Chirco, Anna Cecilia Bettini, Luigi F. Da Pozzo, Ermenegildo Arnoldi |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Oncology Cancer Research medicine.medical_specialty 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Renal cell carcinoma Internal medicine Meningeal Neoplasms Humans Medicine In patient Carcinoma Renal Cell business.industry Treatment options General Medicine Middle Aged medicine.disease Combined Modality Therapy Magnetic Resonance Imaging Kidney Neoplasms Nivolumab Treatment Outcome 030104 developmental biology Meningeal carcinomatosis 030220 oncology & carcinogenesis Tomography X-Ray Computed business Kidney cancer Leptomeningeal metastasis |
Zdroj: | Tumori Journal. 106:NP76-NP78 |
ISSN: | 2038-2529 0300-8916 |
Popis: | Background: Meningeal carcinomatosis is rare in patients with kidney cancer and treatment options are limited. Few patients treated with systemic approaches have been reported. We describe a case of complete remission of leptomeningeal metastasis in a patient with renal cell carcinoma treated with nivolumab. To our knowledge, this is the first report of nivolumab safety and efficacy in this particular site of metastasis. Case presentation: Our patient was a 60-year-old Caucasian man with bone and lung metastases from renal cell carcinoma. He developed leptomeningeal metastasis and progression of bone and lung lesions after only 2 months of his first-line treatment. He was then treated with nivolumab in second-line setting and experienced a rapid improvement of cancer-related symptoms, complete remission of leptomeningeal and lung lesions, and increased bone mineral density in bone metastasis. The patient did not experience any drug-related toxicity. Conclusions: Meningeal carcinomatosis metastasis from renal cancer is a rare condition. Diagnosis is often challenging: the onset of nonspecific presenting symptoms could be initially attributed to bone involvement, side effects of oncologic therapy, or paraneoplastic syndromes. Our case suggests that nivolumab could be an effective and safe treatment option in patients with pretreated renal cancer with leptomeningeal metastasis. |
Databáze: | OpenAIRE |
Externí odkaz: |